We are live on ! Find out more
APTO

Aptose Biosciences

Delisted

APTO was delisted on the 1st of April, 2025.

58 hedge funds and large institutions have $227M invested in Aptose Biosciences in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more call options, than puts

Call options by funds: $507K | Put options by funds: $203K

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

16% more funds holding

Funds holding: 50 → 58 (+8)

12% more capital inflows, than outflows

Capital inflows: $41.6M | Capital outflows: $37.2M

1.01% more ownership

Funds ownership: 46.1% → 47.11% (+1%)

16% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 19

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
58
Holders Change
+8
Holders Change %
+16%
% of All Funds
1.19%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.08%
New
14
Increased
16
Reduced
19
Closed
7
Calls
$507​K
Puts
$203​K
Net Calls
+$304​K
Net Calls Change
+$1.03​M

APTO Hedge Fund Activity: Q2 2020 in Review

58 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q2 2020, worth a combined $227M — up 8.6% from $209M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new APTO positions and 7 closed out — a net gain of 7 holders — while 16 added to existing stakes and 19 trimmed.

The largest buyer was Pictet Asset Management (UK), adding an estimated $9.31M. The largest seller was Polar Capital Holdings, cutting an estimated $13.8M.

  • 58 institutional investors held Aptose Biosciences (APTO) as of Q2 2020, up from 50 in Q1 2020.
  • Funds reported $227M of Aptose Biosciences stock for Q2 2020, up 8.6% quarter-over-quarter.
  • 14 funds opened new Aptose Biosciences positions in Q2 2020 and 7 closed out, a net change of +7 holders.
  • The largest Aptose Biosciences buyer in Q2 2020 was Pictet Asset Management (UK), an estimated $9.31M added.
  • The largest Aptose Biosciences seller in Q2 2020 was Polar Capital Holdings, an estimated $13.8M sold.

Based on aggregated 13F filings for Q2 2020.